Ч.Өнөрцэцэг
Loading...
Товч нэр
Ч.Өнөрцэцэг
Бүтэн нэр
Чандага Өнөрцэцэг
Латин нэр
Chandaga Unurtsetseg
Албан тушаал
Тэнхимийн эрхлэгч
Багш
ORCID
3 results
Now showing 1 - 3 of 3
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Quality Of Hospital Food And Its Safety Assessment(2014-11); ;Delgermaa, V ;Tsevegdorj, T ;Gantuya, BOdongua, N - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Prevalence of Syphilis and HIV Diseases among Some Universities’ Students in Mongolia(David Publishing Company, 2017-12-06); ; ; ;Davaalkam JagdagsurenTungalag MagsarOur country level registered communicable diseases in 2014, 45.6% of them are STD (Sexually Transmitted Diseases).And 43.3% of the affected people by STD are aged between 15-24 years which demonstrated that they have more risky sexual behavior.This study aimed to identify level of prevalence of HIV and Syphilis within university students, to investigate their risky sexual behavior, and to treat them including their sexual partners.The survey included over 1,500 students for screening tests for HIV/Syphilis was performed locally using On Site TM Rapid Test Kits.Through the test not revealed any HIV case, only 40 (2.6%) students diagnosed by syphilis.Screening and confirmation tests for syphilis were performed locally using RPR (Rapid Plasma Reagin) and TPHA (Treponema Palladium Hem agglutination Assay), respectively.The test revealed the diagnosis for first time for 22 (55 %) of those 40 patients with syphilis and 18 (45%) are defined as the control of STD.Therefore, 28 (70%) of them manifested symptoms of STD, only 25 (89.2%) of them previously tested and 9 (32.1%) have not treated at all.The test revealed the diagnosis for first time for 22 (55 %) of those 40 patients with syphilis and 18 (45%) are defined as the control of STD.Finally, above 40 patients are entirely included in treatment with their partners and registered of STD can be controlled. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Bevacizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Mongolian Patients with Diabetic Macular Edema(Mongolian National University of Medical Sciences, 2016-06-25) ;Anaraa Toishubai; ;Baasankhuu Jamyanjav ;Sun Taek LimObjectives: To evaluate the efficacy and safety of bevacizumab monotherapy and bevacizumab therapy combined with laser therapy versus laser monotherapy in Mongolian patients with visual impairment due to diabetic macular edema (DME). Methods: One hundred twelve eligible patients, aged ^18 years, with type 1 or 2 diabetes mellitus and best corrected visual acuity (BCVA) in the study eye of 35 to 69 Early Treatment Diabetic Retinopathy Study letters at 4 m (Snellen equivalent: >6/60 or <6/12), and with visual impairment due to center-involved DME were included in the study. Patients were randomized into three treatment groups: (1) intravitreal bevacizumab monotherapy (n = 42), (2) intravitreal bevacizumab combined with laser therapy (n = 35), and (3) laser monotherapy (n = 35). Bevacizumab injections were given for three initial monthly doses and then pro re nata thereafter based on BCVA stability and DME progression. The primary efficacy endpoints were the mean change in BCVA and central retinal subfield thickness from baseline to month 12. Results: Bevacizumab monotherapy and bevacizumab + laser were superior to laser monotherapy in improving the mean change in BCVA letter score from baseline to month 12 (+8.3 and +11.3 vs +1.1 letters; both p ><0.0001). At month 12, a greater proportion of patients gained >10 and >15 letters and had a BCVA letter score >73 (Snellen equivalent: >6/12) with bevacizumab monotherapy (23.8% and 7.1% and 4.8%, respectively) and bevacizumab + laser (57.1% and 28.6% and 14.3%, respectively) versus laser monotherapy (0% and 0% and 0%, respectively). The mean central retinal subfield thickness was significantly reduced from baseline to month 12 with bevacizumab (-124.4 pm) and bevacizumab + laser (-129.0 pm) versus laser (-62.0 pm; both p = 0.002). Conjunctival hemorrhage was the most common ocular event. No endophthalmitis cases occurred. Conclusion: Bevacizumab monotherapy or bevacizumab + laser showed superior BCVA improvements over macular laser treatment alone in Mongolian patients with visual impairment due to DME.
